Literature DB >> 11337517

Lymphoscintigraphy and sentinel node localization in breast cancer patients: a comparison between 1-day and 2-day protocols.

H W Yeung1, H S Cody III, A Turlakow, E R Riedel, J Fey, M Gonen, R Nuñez, S D Yeh, S M Larson.   

Abstract

UNLABELLED: The purpose of this study was to compare the results of isotope injection the morning of surgery (1-d protocol) with isotope injection the day before surgery (2-d protocol) in patients having sentinel lymph node (SLN) biopsy for breast cancer.
METHODS: The 1-d (protocol 1) and 2-d (protocol 2) protocols included 514 and 152 patients, respectively, treated contemporaneously by surgeons experienced with the SLN biopsy technique. All had preoperative lymphoscintigraphy (LSG) and SLN biopsy using both blue dye and (99m)Tc-sulfur colloid. All patients had a single-site intradermal injection of unfiltered (99m)Tc-sulfur colloid in 0.05 mL normal saline: 3.7 MBq (0.1 mCi) on the morning of surgery for protocol 1 and 18.5 MBq (0.5 mCi) on the afternoon before surgery for protocol 2.
RESULTS: The patients in protocols 1 and 2 were comparable in terms of age, tumor size, tumor location, histologic type, node positivity, and frequency of a previous surgical biopsy. Comparing protocols 1 and 2, early (30 min) LSG images found the SLN equally often (69% vs. 68%). Isotope identified the SLN equally often at surgery (93% vs. 97%) as did isotope plus dye (98% vs. 99%). A comparable number of SLNs was found (2.5 vs. 2.8 per axilla), and the concordance between isotope and dye in the SLN was also comparable (97% vs. 95%). Late LSG images (at 2 h, possible only for protocol 2) identified the SLN in significantly more patients compared with early images (86% vs. 68%).
CONCLUSION: With unfiltered (99m)Tc-sulfur colloid injected intradermally, the results of SLN biopsy under the 1-d and 2-d protocols are virtually identical. A 2-d protocol allows increased efficiency in scheduling, both for nuclear medicine physicians and for the operating room, with no compromise in the effectiveness of SLN mapping.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11337517

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  The influence of wire localisation for non-palpable breast lesions on visualisation of the sentinel node.

Authors:  J E Jansen; J Bekker; M J de Haas; F A van der Weel; G H M Verberne; L M Budel; L G B A Quekel; J M H de Klerk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-28       Impact factor: 9.236

2.  Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek.

Authors:  Anne M Wallace; Carl K Hoh; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2007-08-09       Impact factor: 2.408

3.  Sentinel lymph node accumulation of Lymphoseek and Tc-99m-sulfur colloid using a "2-day" protocol.

Authors:  Anne M Wallace; Carl K Hoh; Karl K Limmer; Denise D Darrah; Gery Schulteis; David R Vera
Journal:  Nucl Med Biol       Date:  2009-08       Impact factor: 2.408

4.  Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy.

Authors:  Adheesh Bhandari; Erjie Xia; Yinghao Wang; Namita Sindan; Ranjan Kc; Yaoyao Guan; Yueh-Lung Lin; Xiaoshang Wang; Xiaohua Zhang; Ouchen Wang
Journal:  Am J Transl Res       Date:  2018-06-15       Impact factor: 4.060

5.  Lymphoscintigraphy and triangulated body marking for morbidity reduction during sentinel node biopsy in breast cancer.

Authors:  Borys R Krynyckyi; Michail K Shafir; Suk Chul Kim; Dong Wook Kim; Arlene Travis; Renee M Moadel; Chun K Kim
Journal:  Int Semin Surg Oncol       Date:  2005-11-08

6.  99mTc-dextran lymphoscintigraphy can detect sentinel lymph node in breast cancer patients.

Authors:  Linlin Wei; Fangni Chen; Xuehui Zhang; Dangsheng Li; Zhongqiang Yao; Liyan Deng; Guoyou Xiao
Journal:  Exp Ther Med       Date:  2014-11-04       Impact factor: 2.447

7.  An Ultralow-Dose 1-Day Protocol With Activities Lower Than 20 MBq for the Detection of Sentinel Lymph Nodes in Breast Cancer-Experiences After 150 Cases.

Authors:  Hans-Christian Kolberg; Shabnam Afsah; Thorsten Kuehn; Ute Winzer; Leyla Akpolat-Basci; Miltiades Stephanou; Sarah Wetzig; Oliver Hoffmann; Cornelia Liedtke
Journal:  Technol Cancer Res Treat       Date:  2017-09-06

8.  Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Breast Cancer: Do We Need a Delayed Image?

Authors:  Nadja Taumberger; Birgit Pernthaler; Thomas Schwarz; Vesna Bjelic-Radisic; Gunda Pristauz; Reingard M Aigner; Karl Tamussino
Journal:  Breast Care (Basel)       Date:  2019-04-29       Impact factor: 2.860

9.  The use of isotope injections in sentinel node biopsy for breast cancer: are the 1- and 2-day protocols equally effective?

Authors:  Nazera Dodia; Deena El-Sharief; Cliona C Kirwan
Journal:  Springerplus       Date:  2015-09-15

10.  Hybrid (2D/3D) Dosimetry of Radiolabeled Gold Nanoparticles for Sentinel Lymph Node Detection in Patients with Breast Cancer.

Authors:  Gerardo Ramírez-Nava; Clara Santos-Cuevas; Guillermina Ferro-Flores; Blanca Ocampo-García; Isaac Chairez; Edgar Gómez-Argumosa; Lucero Abundiz-López; Francisco O García-Pérez
Journal:  Contrast Media Mol Imaging       Date:  2020-05-06       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.